Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with advanced
anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the tumor.